<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2249D655-CA3E-4E53-ABB3-958243368C30"><gtr:id>2249D655-CA3E-4E53-ABB3-958243368C30</gtr:id><gtr:name>MicroDiscovery GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/44066C0A-2DBD-4F1F-AD28-10D874470FB1"><gtr:id>44066C0A-2DBD-4F1F-AD28-10D874470FB1</gtr:id><gtr:name>Matrix Science</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D0D94042-003F-4348-A7AE-F2FA0D012435"><gtr:id>D0D94042-003F-4348-A7AE-F2FA0D012435</gtr:id><gtr:name>Royal Berkshire NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Royal Berkshire Hospital</gtr:line1><gtr:line2>London Road</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG1 5AN</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E89C3602-0FB4-4044-A918-58966B8A10B2"><gtr:id>E89C3602-0FB4-4044-A918-58966B8A10B2</gtr:id><gtr:name>University of Reading</gtr:name><gtr:department>Sch of Biological Sciences</gtr:department><gtr:address><gtr:line1>Whiteknights House</gtr:line1><gtr:line2>PO Box 217</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG6 6AH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E89C3602-0FB4-4044-A918-58966B8A10B2"><gtr:id>E89C3602-0FB4-4044-A918-58966B8A10B2</gtr:id><gtr:name>University of Reading</gtr:name><gtr:address><gtr:line1>Whiteknights House</gtr:line1><gtr:line2>PO Box 217</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG6 6AH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2249D655-CA3E-4E53-ABB3-958243368C30"><gtr:id>2249D655-CA3E-4E53-ABB3-958243368C30</gtr:id><gtr:name>MicroDiscovery GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44066C0A-2DBD-4F1F-AD28-10D874470FB1"><gtr:id>44066C0A-2DBD-4F1F-AD28-10D874470FB1</gtr:id><gtr:name>Matrix Science</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D0D94042-003F-4348-A7AE-F2FA0D012435"><gtr:id>D0D94042-003F-4348-A7AE-F2FA0D012435</gtr:id><gtr:name>Royal Berkshire NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Royal Berkshire Hospital</gtr:line1><gtr:line2>London Road</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG1 5AN</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A0057880-03F1-40EE-9BB5-E0EFA7E2D0A7"><gtr:id>A0057880-03F1-40EE-9BB5-E0EFA7E2D0A7</gtr:id><gtr:firstName>Vladimir</gtr:firstName><gtr:surname>Vovk</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C0E3450E-D2AA-4F44-B433-E8B25138484D"><gtr:id>C0E3450E-D2AA-4F44-B433-E8B25138484D</gtr:id><gtr:firstName>Zhiyuan</gtr:firstName><gtr:surname>Luo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B3CFAB86-E47C-4A51-BF72-E26E833B6951"><gtr:id>B3CFAB86-E47C-4A51-BF72-E26E833B6951</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Gayther</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AFA2AF93-7D94-45EC-98FC-37927335D6AD"><gtr:id>AFA2AF93-7D94-45EC-98FC-37927335D6AD</gtr:id><gtr:firstName>Usha</gtr:firstName><gtr:surname>Menon</gtr:surname><gtr:orcidId>0000-0003-3708-1732</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1C19F7AF-5A4B-4B2D-A649-3A45425290A4"><gtr:id>1C19F7AF-5A4B-4B2D-A649-3A45425290A4</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Jacobs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/78EEF17D-BB75-4D61-A77A-7F46A86FA676"><gtr:id>78EEF17D-BB75-4D61-A77A-7F46A86FA676</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Waterfield</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/49325518-D349-4D23-9EB7-EFAAA2D78759"><gtr:id>49325518-D349-4D23-9EB7-EFAAA2D78759</gtr:id><gtr:firstName>Rainer</gtr:firstName><gtr:otherNames>Karl</gtr:otherNames><gtr:surname>Cramer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/42D0C9AE-E23A-4FE4-894D-15D39140088B"><gtr:id>42D0C9AE-E23A-4FE4-894D-15D39140088B</gtr:id><gtr:firstName>Alexander</gtr:firstName><gtr:surname>Gammerman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90A900FE-EE31-4072-A57B-271596A42AA3"><gtr:id>90A900FE-EE31-4072-A57B-271596A42AA3</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Francis</gtr:otherNames><gtr:surname>Timms</gtr:surname><gtr:orcidId>0000-0002-4507-835X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0301107"><gtr:id>C0785EF9-420E-4E1C-A01F-3CB4529A0AB7</gtr:id><gtr:title>Proteomic Analysis of the Human Serum Proteome - Reading component</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0301107</gtr:grantReference><gtr:abstractText>Variations in the blood proteome, i.e. the set of proteins in the blood, occur continuously, reflecting the normal function of the body as well as abnormalities in disease. The many thousands of different proteins in the blood are released from the tissues and organs as the blood continuously circulates around the body. Subtle changes in the pattern of the blood proteome occur in cancer and in other common diseases and can be used for early detection of disease. Until recently it has only been possible to detect a small proportion of these changes by using an individual test for each of the small number of known proteins. Exciting developments in proteomic technology now provide the opportunity to analyse all of the many thousands of proteins in the serum simultaneously providing a ?fingerprint? of the entire circulating proteome. This opens up great opportunities for the development of powerful screening tests based upon differences in the proteomic pattern which occur in individuals with disease and healthy individuals. The complexity of the blood serum proteome and the very low levels of the abnormal proteins create considerable obstacles in realising the potential of this technology. This project will assess the performance of cutting edge proteomic technology for screening and diagnosis utilising a unique serum bank collected from 200,000 women involved in a cancer screening programme. In Phase I, the reliability of the available techniques will be assessed. The most promising technique will be used in Phase II to identify the ?fingerprint? patterns of protein changes in common and important diseases including breast cancer, colorectal cancer, ovarian cancer, heart disease and deep vein thrombosis and to determine the accuracy of serum proteomic analysis for early detection of these diseases. In Phase III, the identity of the proteins responsible for the disease related fingerprints will be established and in Phase IV the findings will be related to genetic and proteomic factors already identified in other studies of cancer and cardiac disease. The objective is to document proteomic ?fingerprints? which can identify individuals with cancer, heart disease and other disorders sufficiently early to allow effective treatment and save lives.</gtr:abstractText><gtr:technicalSummary>This proposal is designed to establish the potential of the human serum proteome for screening and diagnosis in large populations using existing cutting-edge technologies for high-throughput protein analysis and biomarker discovery. Recent publications have suggested that serum proteomic analysis has great potential for diagnosis and early detection of human disease. However, these studies have been criticised because of the absence of a systematic approach carefully assessing the numerous variables in sample handling, instrument performance and data analysis as well as concerns about sample selection. We will systematically assess several technologies (including SELDI, nanoESI/Advion and microfluidic sample preparation/Gyrolab) for analysis of the serum proteome utilising powerful data management/bioinformatics approaches and the unique MRC funded UKCTOCS serum bank prospectively collected from 200,000 postmenopausal women. Phase I of the project will assess the impact of sample preparation, physiological variation and instrument variation on the results of proteomic analysis and identify the optimal technology for further studies. Phase II will apply the optimal proteomic technology to case control sample sets in the UKCTOCS serum bank to establish the diagnostic and screening potential of the technology for cancers (eg. breast, colon, ovary) and other common disorders (eg. MI, DVT). In Phase III the biomarkers responsible for the disease-specific patterns documented in Phase II will be identified so that antibodies can be produced and robust clinical screening tools developed. The proposal, which will also link into our ongoing genomic studies of disease risk susceptibility and prognostic prediction in Phase IV, brings together groups with established expertise in proteomics, bioinformatics, data management, population screening and molecular genetics as well as building on the value of the UKCTOCS serum bank. Most of the mass spectrometry/proteomics equipment required for the study is available within our group. The funding required (#~1.3m over 3 years) is therefore primarily for consumables and staff with a component for additional equipment.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>492429</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MicroDiscovery GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>System-wide analysis and modelling of protein modification</gtr:description><gtr:id>DADBFF07-4B9B-4B80-BFBC-CA1A6DB9D3D6</gtr:id><gtr:impact>Successful FP6 STREP application</gtr:impact><gtr:outcomeId>DC723E50399-1</gtr:outcomeId><gtr:partnerContribution>bioinformatic analysis of our data</gtr:partnerContribution><gtr:piContribution>System-wide analysis and modelling of protein modification</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Berkshire NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Biomarker Discovery in Men's Cancer</gtr:description><gtr:id>8E309A27-8CA4-472C-8B2A-C029E48E1250</gtr:id><gtr:impact>Several poster presentations and one trade journal publication</gtr:impact><gtr:outcomeId>eMx8jdG4tpf-1</gtr:outcomeId><gtr:partnerContribution>Samples and clinical expertise</gtr:partnerContribution><gtr:piContribution>Supervision of PhD student and expertise in MS-based proteomic analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Matrix Science</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Matrix Science</gtr:description><gtr:id>8A9F49D6-335C-4C3D-BF3E-83ABCD584FC0</gtr:id><gtr:impact>Debelopment of new software</gtr:impact><gtr:outcomeId>D2AC2EE91ED-1</gtr:outcomeId><gtr:partnerContribution>free LIMS system and software support</gtr:partnerContribution><gtr:piContribution>Data provision and software testing</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Discussion of industrial support</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D8C01B14-4FFB-4A59-95BB-9E6FA903CC84</gtr:id><gtr:impact>Presentation of our research to industry

Ongoing.</gtr:impact><gtr:outcomeId>183A6E1D1B7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2006,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>MALDI MS serum profiling peak identification table</gtr:description><gtr:id>CEDAF00A-ADD8-4691-B53E-3590E8711CD7</gtr:id><gtr:impact>TBD</gtr:impact><gtr:outcomeId>620C9578BBE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Peak ID table</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Standard operating protocol for automated and robust serum peptide profiling using small serum volumes (i.e. 5uL)</gtr:description><gtr:id>184C7158-5452-4E39-8753-D4C9497C8532</gtr:id><gtr:impact>Significant interest from the clinical research/diagnostics community; led to several discussions for applying it in other future research programmes; modified protocol has been applied in an EU-funded systems biology project</gtr:impact><gtr:outcomeId>3F237558550</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SOPs</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E06DAE91-A4F1-45D6-97E7-263E8A6CDF2F</gtr:id><gtr:title>Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.</gtr:title><gtr:parentPublicationTitle>Cancer genomics &amp; proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56661fabeab58b91bce97c183c6571d"><gtr:id>d56661fabeab58b91bce97c183c6571d</gtr:id><gtr:otherNames>Timms JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1109-6535</gtr:issn><gtr:outcomeId>pm_13704_24_22086897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61B49305-1307-4FA3-B58D-DEE724A41AA1</gtr:id><gtr:title>Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd7cc15bf278cda9234660cde466127"><gtr:id>2cd7cc15bf278cda9234660cde466127</gtr:id><gtr:otherNames>Tiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>744AD6200B5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>743F01CF-A4AD-485D-8252-3BB16F7DD48E</gtr:id><gtr:title>MALDI MS.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ab92ef3878314b0c036018564e7e9e"><gtr:id>52ab92ef3878314b0c036018564e7e9e</gtr:id><gtr:otherNames>Cramer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_13704_14_19544018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F29AD85-2577-423A-B798-6D2F3AAEFA5C</gtr:id><gtr:title>On-line predictive linear regression</gtr:title><gtr:parentPublicationTitle>The Annals of Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78d2f0d473b0b2ade2a52a6fecc2b1e5"><gtr:id>78d2f0d473b0b2ade2a52a6fecc2b1e5</gtr:id><gtr:otherNames>Vovk V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>doi_55f983983794ab4e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4665D25B-7827-4FA2-A679-21E423F2D41E</gtr:id><gtr:title>A well-characterised peak identification list of MALDI MS profile peaks for human blood serum.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd7cc15bf278cda9234660cde466127"><gtr:id>2cd7cc15bf278cda9234660cde466127</gtr:id><gtr:otherNames>Tiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>QQ5jFFNYNLi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EF6E9D4-6AAD-436F-9B8A-88C9EB7BCF93</gtr:id><gtr:title>Multiprobabilistic prediction in early medical diagnoses</gtr:title><gtr:parentPublicationTitle>Annals of Mathematics and Artificial Intelligence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c763fa7fba379979484285324d63a1be"><gtr:id>c763fa7fba379979484285324d63a1be</gtr:id><gtr:otherNames>Nouretdinov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5675fc49f07de</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9710B90-3148-4BDD-A58C-D472A61E11BB</gtr:id><gtr:title>Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56661fabeab58b91bce97c183c6571d"><gtr:id>d56661fabeab58b91bce97c183c6571d</gtr:id><gtr:otherNames>Timms JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9147</gtr:issn><gtr:outcomeId>SDnn1toxsJW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44BD47B9-70F6-4061-B0E1-EE23B33D3BA1</gtr:id><gtr:title>Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd7cc15bf278cda9234660cde466127"><gtr:id>2cd7cc15bf278cda9234660cde466127</gtr:id><gtr:otherNames>Tiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn><gtr:outcomeId>oZySXWYAxRa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F813D437-686C-4FA9-B5CC-87D38F9FFE94</gtr:id><gtr:title>Leading strategies in competitive on-line prediction</gtr:title><gtr:parentPublicationTitle>Theoretical Computer Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78d2f0d473b0b2ade2a52a6fecc2b1e5"><gtr:id>78d2f0d473b0b2ade2a52a6fecc2b1e5</gtr:id><gtr:otherNames>Vovk V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>doi_55f983983783a649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4687E70-21D7-41ED-8F53-82F9F09B0D19</gtr:id><gtr:title>Determining confidence of predicted interactions between HIV-1 and human proteins using conformal method.</gtr:title><gtr:parentPublicationTitle>Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c763fa7fba379979484285324d63a1be"><gtr:id>c763fa7fba379979484285324d63a1be</gtr:id><gtr:otherNames>Nouretdinov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2335-6928</gtr:issn><gtr:outcomeId>pm_13704_24_22174286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BBEA61A-B661-4C64-9C17-14E4FB4845C0</gtr:id><gtr:title>Mass spectrometry in clinical proteomics - from the present to the future.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b1ba24a0d948f208b9bb843aea0bc39"><gtr:id>5b1ba24a0d948f208b9bb843aea0bc39</gtr:id><gtr:otherNames>Palmblad M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>1E3B0FE908F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A8BDC80-EE6E-41D7-AC2C-CEAC61F6CE4D</gtr:id><gtr:title>Serum Proteomic Abnormality Predating Screen Detection of Ovarian Cancer</gtr:title><gtr:parentPublicationTitle>The Computer Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbed0507bb5763c3f73c6aa548d50a77"><gtr:id>cbed0507bb5763c3f73c6aa548d50a77</gtr:id><gtr:otherNames>Gammerman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>AD0F66C7F73</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0301107</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>